Is there a role for influenza vaccination in cystic fibrosis?  by Wat, Dennis et al.
Journal of Cystic Fibrosis 7 (2008) 85–88
www.elsevier.com/locate/jcfShort communication
Is there a role for influenza vaccination in cystic fibrosis?
Dennis Wat a,⁎, Colin Gelder b, Sam Hibbitts c, Ian Bowler d,
Marcus Pierrepoint e, Rachel Evans f, Iolo Doull a
a Department of Cystic Fibrosis, University Hospital of Wales, Cardiff, UK
b Llandough Hospital, Penarth, UK
c University of Wales College of Medicine, Cardiff, UK
d Royal Gwent Hospital, Newport, UK
e Neville Hall Hospital, Abergavenney, UK
f Singleton Hospital, Swansea, UK
Received 7 March 2007; received in revised form 22 April 2007; accepted 7 May 2007
Available online 5 July 2007Abstract
Background: Influenza vaccination is generally recommended to patients with Cystic Fibrosis (CF). Previous studies have shown that
influenza infections cause worsening lung functions, disease progression and increase propensity of bacterial infections in CF. However, the
clinical evidence in the effectiveness of influenza vaccination in CF is lacking.
Aims: This study retrospectively reviewed the influenza vaccination status in the patients with CF and compared the influenza infection rates
between the vaccinated and non-vaccinated groups. Finally the factors associated with non-adherence with vaccination were determined.
Methods: Nasal swabs were obtained from 63 patients with CF between the age of 6 months to 18 years routinely and during respiratory
exacerbations between October 2003 to April 2004. Influenza A and Influenza B were detected using Nucleic Acid Sequence Based
Amplification (NASBA). The influenza vaccination status of these patients was retrospectively reviewed.
Results: 41 patients (65%) were vaccinated against influenza. For the 22 patients (35%) who were not vaccinated, 7 of them were scared of
needles leading to non-adherence. Influenza virus was detected on 5 occasions; 3 were Influenza A (60%) and 2 were Influenza B (40%). 1
virus in the vaccinated group and 4 in the non-vaccinated were detected during the study period ( p-value=0.046).
Conclusions: Although the current available evidence to support routine influenza vaccination is limited in CF, this study has shown that
such practice may yet play a role in preventing its subsequent acquisition.
Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Influenza vaccination; Cystic fibrosis; NASBA1. Background
Cystic Fibrosis (CF) is a common autosomal recessive
inherited disease with progressive obstructive lung disease
being the main cause of death in 95% of the patients [1].
Bacteria play an important role in producing airway damage
and altering pulmonary function, with Pseudomonas aerugi-
nosa being the major pathogen [2]. However, there is evidence
in the literature that exacerbations in CF are associated with⁎ Corresponding author. Department of Cystic Fibrosis, University Hospital of
Wales,HeathPark,CardiffCF14 4XW,UnitedKingdom.Tel.: +44 2920747747.
E-mail address: denniswat118@hotmail.com (D. Wat).
1569-1993/$ - see front matter. Published by Elsevier B.V. on behalf of Europea
doi:10.1016/j.jcf.2007.05.002non-bacterial pathogens including respiratory viruses which
have been implicated in contributing to pulmonary exacerba-
tions. Influenza viruses [3 4 5] in particular have been shown to
cause disease progression in CF by contributing to worsening
in lung function, increasing hospitalisation rates [4] and
predisposing to bacterial infections [3].
There are two types of influenza viruses; A and B, which
are distinguished by the antigenicity of the ribonucleoprotein
core and the internal non-glycosylated matrix protein layer.
Influenza A viruses are further subdivided into subtypes on
the basis of their surface glycoproteins, haemagglutinin and
neuraminidase proteins. One of the most remarkable and
unique features of influenza viruses is the ability to exhibitn Cystic Fibrosis Society.
Table 1
Reasons used to define respiratory exacerbations
Reasons used to define respiratory
exacerbations
Vaccinated
group
Non-vaccinated
group
p-value
Symptom score totalled N4 26 (87%) 7 (47%) 0.001
Peak flow fell N50 l/min
from usual best
3 (10%) 5 (33%) 0.09
Subjective feeling of coming
down with a cold
1 (3%) 3 (20%) 0.1
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host defence mechanisms, heralding epidemic and pandemic
outbreaks, respectively.
Influenza immunisation is generally advised to all
patients with CF. However, there is no existing study that
shows the benefits of influenza vaccination given to patients
with CF [6]. The lack of clinical evidence to support its use
in CF prompted this retrospective review with the following
generated objectives:
1. To look at the incidence of influenza acquisition between
the vaccinated and non-vaccinated patients during the
influenza season.
2. To evaluate the rates of respiratory exacerbations in the
vaccinated and non-vaccinated groups.
3. To study the differences in symptom complaints between
the two groups.
4. To investigate the reasons for non-adherence to
vaccination.
2. Method
Patients in this review were between the ages of 6 months
to 18 years from four CF centres namely University Hospital
of Wales in Cardiff, UK, Royal Gwent Hospital in Newport,
UK, Neville Hall Hospital in Abergavenney, UK, and
Singleton Hospital in Swansea, UK. They were part of a
prospective study looking at the prevalence of respiratory
viruses in CF. Informed consent was obtained from all
participants. This study received ethical approval from each
of the institution's ethics committee. The immunisation
status of the patients and reasons for non-adherence were
retrospectively obtained from the patients or their parents at
the end of the study.
The influenza season was determined by the European
Influenza Surveillance Scheme to be between October 2003
and April 2004. Patients who were vaccinated before this
period and the ones who were not vaccinated were included
in this review.
Nasal swabs were obtained from the patients whenever
they developed symptoms suggestive of respiratory exacer-
bations and whenever they attended for routine assessment
between 1st October 2003 to 30th April 2004 (7 month
duration). Each nasal swab was obtained by inserting a
sterile cotton wool swab into one of the nostrils to a depth of
2 to 3 cm. The swab was then subjected into 500 μl of
guanidium thiocyanate lysis buffer. It was transported with
ice packs to the laboratory and then stored at −80 °C until
undergoing nucleic acid extraction at a later date.
Influenza A and B nucleic acid materials were extracted
from the nasal swabs using silica slurry as described by
Boom et al. [8]. Extracted materials were amplified at ‘real-
time’ using Nucleic Acid Sequence Based Amplification
(NASBA) in conjunction with molecular beacons [9].
Analysis of results was undertaken using the NucliSens®
Easy Q Analyser (BioMérieux Ltd) isothermically at 41 °Cfor 120 minutes. The sensitivities of the ‘real-time’ assays
were found to be within the range of 0.1–0.0150% tissue
culture infective dose (TCID50) virus input and 100–1 copies
of synthetic RNA. The cut-off threshold for a positive result
was defined as 20% above the negative control wild-type
signal [9].
In this study, each patient (and parents) had been provided
with a symptom diary card which comprised of upper and
lower respiratory symptoms that included runny nose,
blocked nose, sore throat, hoarse voice, fever/shivering,
cough (daytime and night-time), wheeze (daytime and night-
time), shortness of breath and school absenteeism. Patients
and parents had been asked to score their symptoms using
the diary card regularly. The symptom score ranged from 0
(no symptoms) to 3 (severe symptoms) for each criteria.
Each patient above the age of 5 years was also provided with
a mini-Wright Peak Flow Meter and was asked to record the
best of three readings every morning and evening.
The definition of a ‘respiratory exacerbation’ was when:
1) the symptom score totalled to 4 or more, or 2) if peak
expiratory flow fell by more than 50 l/min from the child’s
usual best value, or 3) if the parent subjectively felt that the
child was developing a cold [7]. Under these circumstances,
the parents or patients were encouraged to contact the
investigators to have a nasal swab taken. Throughout the
study period, both the parents and patients received
telephone and written reminders to contact the investigators
in the event of a respiratory exacerbation.
During the season 2003/2004, a trivalent influenza vac-
cine was used, the composition of which included: an A/
Moscow/10/99(H3N2)-like strain, an A/New Caledonia/20/
99 (H1N1)-like strain and a B/Hong Kong/330/2001-like
strain. The majority of circulating strains isolated in 2003/
04 showed a partial match with the corresponding influen-
za vaccine component. The influenza A Fujian/411/2002
(H3N2)-like subtype that predominated in the UK was not
included in the vaccine, but a degree of cross protection was
offered by the influenza A (H3N2) strain that was included in
the vaccine.
Fisher's exact test was used in analysing the influenza
identification rates, the respiratory exacerbation rates and the
differences in symptomology between the vaccinated and non-
vaccinated groups using the software package GraphPad
InStat version 3.0 for windows (GraphPad software, San
Diego, CA).
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Sixty-three patients were included in this review with the
average age at 9.9 (SD±5) years. Twenty-five (40%) of them
were females. Forty-one patients (65%) were vaccinated
with a mean age of 11.5 (SD±4) years. Within this group,
fifteen (37%) patients were female. In contrast, twenty-two
(35%) patients were not vaccinated with a mean age of 7.0
(SD±5) and ten (45%) were females.
Forty-one nasal swabs were obtained from forty-five
reported episodes of respiratory exacerbations. There were
also twenty-nine routine samples submitted, giving a total of
seventy samples being analysed by NASBA. Five influenza
viruses (7%) were identified from these samples and they all
belonged to the exacerbation group with no viruses identified
from the routine group. Three of the viruses were influenza A
(60%) and twowere influenza B (40%). Four influenza viruses
(80%) were identified in the non-vaccinated group compared
to one (20%) in the vaccinated group (p-value=0.046), giving
a relative risk of 0.13.
Thirty of the forty-five episodes (73%) of respiratory
exacerbations were reported by the vaccinated group with
fifteen (68%) from the non-vaccinated group (p-value=0.772).
In the 10 months prior to this review, the respiratory
exacerbation rates between the vaccinated and non-vaccinated
groups were similar, 2.9 per patient per year in the vaccinated
group versus 3.3 per patient per year in the non-vaccinated
group.
Table 1 summarises the reasons used for defining
respiratory exacerbations in the vaccinated and non-vaccinated
groups. There were significantly more patients in the
vaccinated group using the summated symptom score to
define exacerbations, twenty-six of the thirty episodes (87%)
of exacerbations in the vaccinated group in comparison to
seven of the fifteen episodes (47%) in the non-vaccinated
group (p=0.001). The mean symptom score during respira-
tory exacerbations in the vaccinated group was 5 compared to
that of the non-vaccinated group at 8. However, where there
was a positive influenza virus identified, the mean symptom
scores of the two groups were identical at 8. There were aTable 2
Frequencies of upper and lower respiratory tract symptoms reported by
vaccinated and non-vaccinated groups
Symptoms
reported
Vaccinated group
(n=22)
Non-vaccinated group
(n=7)
p-value
Runny nose 14 (54%) 7 (100%) 0.03
Blocked nose 13 (50%) 4 (57%) 1
Sore throat 5(19%) 5 (71%) 0.016
Hoarse voice 2 (8%) 1 (14%) 0.52
Fever/shivery 10 (38%) 4 (57%) 0.42
Cough during the day 14 (54%) 5 (71%) 0.67
Cough at night 8 (31%) 4 (57%) 0.38
Wheeze during
the day
7 (27%) 4 (57%) 0.18
Wheeze at night 2 (8%) 1 (14%) 0.52
School absenteeism 4 (15%) 2 (29%) 0.58slightly higher proportion of patients using peak expiratory
flow reduction to define an exacerbation in the non-vaccinated
group.
Table 2 summarises the symptoms recorded in the diary
card between the vaccinated and non-vaccinated groups
during respiratory exacerbations. There was a higher
proportion of patients in the non-vaccinated group complain-
ing of upper respiratory tract symptoms such as runny nose
(54% versus 100%, p=0.03) and sore throat (19% versus
71%, p=0.016) during exacerbations. The frequencies in
lower respiratory tract complaints were otherwise similar
between the two groups.
For the 22 patients who were not vaccinated, 5 (23%) of
them forgot, 7 (32%) were scared of needles, 1 (4%) was
worried about side effects, 6 (27%) were too unwell to be
vaccinated and 3 (14%) did not feel influenza vaccination
was effective.
4. Discussion
This review suggests that influenza vaccination offers
protection against influenza acquisition in patients with CF,
with significantly more non-vaccinated patients having a
positive nasal swab for influenza (p=0.046). Although in-
fluenza vaccination does not appear to have any impact on
respiratory exacerbation rates, it does have a role in preventing
live infections. However, the results have to be handled with
care because of the small study sample.
Thus far the clinical evidence to support the use of influenza
vaccination in patients with CF is limited. A recent Cochrane
review [6] of 4 randomised trials comparing any influenza
vaccine with a placebo or with another type of influenza
vaccine inCF did not show any clinical benefits in vaccination.
It therefore concluded that the available evidence did not
support national recommendations of vaccinating these
patients, although many CF units recommend their patients
of receiving annual influenza vaccination.
The clinical evidence to support the routine use of influenza
vaccination in other chronic respiratory diseases such as
asthma is similarly lacking. A Cochrane review in influenza
vaccination in asthma showed that there was no immediate
increase in asthma exacerbation rate in the 2 weeks following
vaccination [10]. However, a randomised placebo-controlled
trial did not show a significant reduction in number, severity or
duration of asthma exacerbations caused by viralogically
proven influenza infection despite vaccination. In addition,
there was no difference in respiratory symptoms between
vaccination group and placebo group [11].
In contrast, influenza vaccination in patients with chronic
obstructive pulmonary disease (COPD) led to a significant
reduction in the total number of exacerbations compared to
those who received placebo (p=0.006). There was also no
increase in early exacerbations following vaccination [12].
In this study, respiratory exacerbation rates in the pre-
ceding 10 months before the study between the vaccinated
and non-vaccinated groups were similar, indicating that these
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immunisation. The decision may be down to a combination
of patient/ parent education, social background, awareness of
vaccination and accessibility of vaccination. There were
significantly more patients in the vaccinated group using
increased symptoms to define respiratory exacerbations; this
may be that they had a higher perception and awareness of
increased respiratory symptoms. Although the non-vacci-
nated group had a higher mean symptom score during ex-
acerbations compared to the vaccinated group, this difference
was no longer present during positive influenza infection
episodes.
The non-vaccinated group had significantly more upper
respiratory tract symptoms such as runny nose and sore
throat during respiratory exacerbations compared to the
vaccinated group, but there was no difference in terms of
lower respiratory complaints. In view of this, intranasal
vaccination maybe an effective and attractive option as this
will offer local protection in the upper airways and can help
arrest infection at an early phase before symptom complica-
tions arise.
Regarding the reasons for not being vaccinated, needle
phobia was cited as the commonest reason for non-adherence.
This was a somewhat surprising observation as many of these
patients were used to the vigorous blood test investigations and
intravenous antibiotics as part of their treatment regime.
Maybe the intramuscular route of administration posed a less
attractive option, especially as some of these patients had low
muscle mass and were less likely to tolerate pain at the site of
injection.
Previous studies have demonstrated the detrimental
effects of influenza on CF. A retrospective study conducted
by Pribble et al. [4] showed that infection with influenza A
virus led to a higher proportion of CF patients with a 20%
decrease in forced expiratory volume per second and forced
expiratory flow in first 25% of vital capacity than patients
with other non-bacterial infection and the group without non-
bacterial infection (p-valueb0.05 for all comparisons).
Conway and colleagues [3] also reported similar findings.
Immunisation against influenza A virus has been shown to
provoke an adequate antibody response in patients with CF
[13]. Rapid diagnostic tests may have a role in infection
control; the use of anti-virals, such as neuraminidase inhib-
itors, requires prompt detection of influenza though their role
in CF is not yet defined. NASBA as used in this review offers
greater sensitivity and specificity than traditional laboratory
methods such as direct immunofluorescence (IF) and cell
culture [14]. It also has several advantages over PCR in that it
is a continuous isothermic process that does not require a
thermocycler. It also allows targeted RNA to be amplified
exponentially at each step of the reaction and hence more
efficient than PCR methods that are restricted to binary
increases per cycle. Finally, the closed-tube format of NASBA
assay greatly reduces the risk of contamination and thus of
false-positive results.In conclusion, despite the lack of randomised placebo
controlled trial addressing the effectiveness of influenza
vaccination in CF, this review demonstrated the protective
effect of influenza vaccination in patients with CF. Therefore
annual influenza vaccination should be routinely offered to
these patients as part of their management.
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